We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Maryland-based Novavax has signed an agreement with Fujifilm Diosynth Biotechnologies to manufacture the bulk drug substance for Novavax’s COVID-19 vaccine candidate NVX-CoV2373. Read More
Gilead Sciences said it is buying a 49.9 percent stake in Tizona Therapeutics, a company developing first-in-class cancer immunotherapies, for $300 million in a transaction expected to close in the third quarter of this year. Read More
HHS and the Department of Defense have signed their largest deal to date under Operation Warp Speed — a $1.95 billion contract with Pfizer and BioNTech for large-scale production and nationwide delivery of 100 million doses of their COVID-19 vaccine. Read More
Roche has signed a $1.7 billion agreement with Blueprint Medicines to develop and commercialize Blueprint’s pralesetinib for treatment of patients with RET-altered cancers. Read More
Even in the midst of the COVID-19 pandemic, some drugmakers have continued to impose price hikes, raising the list prices for 42 branded drugs by an average of 3.5 percent in July so far, according to a drug price watchdog. Read More
Moderna has tapped Spanish pharma company Laboratorios Farmacéuticos Rovi to conduct large-scale, commercial fill-finish manufacturing of its COVID-19 vaccine candidate in order to bolster international supply. Read More
The federal government has granted two contracts worth more than $2 billion as part of Operation Warp Speed — $1.6 billion to Novavax to manufacture and develop its COVID-19 vaccine candidate, and $450 million to Regeneron Pharmaceuticals to manufacture and supply its antibody cocktail to treat COVID-19. Read More